Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study (scientific article published on 01 July 2011)

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Q27860904

Sorafenib in advanced hepatocellular carcinoma

Q27861075

Sorafenib in advanced clear-cell renal-cell carcinoma

Q28282767

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Q29617585

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

Q29617640

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

Q30429122

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

Q33384029

Cancer burden in the year 2000. The global picture

Q34402117

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

Q36610990

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer

Q36623268

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Q37278365

Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.

Q39637482

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors

Q40182316

Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer.

Q40343201

A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.

Q42759889

Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

Q42805124

Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium

Q42905241

Salvage therapy with topotecan in heavily pretreated ovarian cancer patients

Q46228021

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

Q46904135

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

Q52581305

Vascular endothelial growth factor expression in early stage ovarian carcinoma

Q53359012

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Q53965542

Sample Size Estimation: How Many Individuals Should Be Studied?

Q73356424

Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma

Q80565368

P433

issue

P921

main subject

ovarian cancer

Q172341

P304

page(s)

33-36

P577

publication date

2011-07-01

P1433

published in

Gynecologic Oncology

Q5625182

P1476

title

Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study

P478

volume

123

Reverse relations

cites work (P2860)

Q52628568	A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.
Q51065459	A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
Q35205410	Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.
Q38813996	Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.
Q98386430	Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism
Q38038489	Clinical trials and future potential of targeted therapy for ovarian cancer
Q39710264	Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy
Q91789025	Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study
Q36270115	Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review
Q37185385	Network analysis identifies an HSP90-central hub susceptible in ovarian cancer
Q35837949	Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways
Q48012324	Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma
Q90408668	Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
Q26751280	Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
Q87424383	Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer
Q98164379	Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Q50345037	The rise of genomic profiling in ovarian cancer
Q36910794	Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
Q37610081	Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib

P356	DOI	10.1016/J.YGYNO.2011.06.019
P698	PubMed publication ID	21723597